A phase 3, randomised, double-blind study of Trilaciclib or placebo in patients receiving first or second line Gemcitabine and Carboplatin chemotherapy for locally advanced unresectable or metastatic triple-negative breast cancer [G1T28-208] [PRESERVE 2].